Clinical Trials Browser

Paraganglioma × Axitinib × Endocrine × Clear all

NCT01967576 2021-01-06

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Phase 2 Completed

14 enrolled 12 charts

Paraganglioma, Pheochromocytoma